Compare Gilead Sciences, Inc. (GILD) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs HCA Health Inc — how do they compare? Gilead Sciences, Inc. trades at $133.03 (market cap $163.51B), while HCA Health Inc trades at $390.94 (market cap $84.04B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | HCA | |
|---|---|---|
Market Cap | $163.51B | $84.04B |
Sector | Health | Health |
52-Week High | $155.80 | $545.13 |
52-Week Low | $108.22 | $334.32 |
Enterprise Value | $178.05B | $132.95B |
Dividend Yield | 2.49% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HCA Healthcare (HCA) is trading at $363.60, down 6.95% amid lowered 2026 guidance. The stock shows bearish technical signals but maintains strong fundamentals with consistent revenue growth to $75.6 billion in 2025 and earnings beats in recent quarters. Analyst consensus remains bullish with a $469.40 price target despite recent negative sentiment from payer mix challenges.
The outlook presents a value opportunity given attractive valuation multiples (P/E 13.05, EV/EBITDA 8.48) and dividend yield, though risks include rising uninsured patients and margin compression. Long-term growth drivers include capacity expansion and specialty care investments, but near-term volatility may persist until Q2 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
